Talus Bio
Talus Bio turns previously undruggable transcription factors into therapeutic targets by directly measuring and modulating the cellular regulome. The company’s MARMOT platform combines functional proteomics, automated biology, synthetic chemistry, and machine learning to generate large-scale functional datasets in living human cells and design candidate molecules. Talus Bio focuses on drug discovery for oncology and other diseases driven by genome regulators, including autoimmunity and neurodegeneration. The company partners with pharmaceutical and biotechnology organizations to advance therapeutics.
Talus Bio
Talus Bio turns previously undruggable transcription factors into therapeutic targets by directly measuring and modulating the cellular regulome. The company’s MARMOT platform combines functional proteomics, automated biology, synthetic chemistry, and machine learning to generate large-scale functional datasets in living human cells and design candidate molecules. Talus Bio focuses on drug discovery for oncology and other diseases driven by genome regulators, including autoimmunity and neurodegeneration. The company partners with pharmaceutical and biotechnology organizations to advance therapeutics.
TL;DR
Founded: 2020
Headquarters: Seattle, WA
Focus: Drug discovery targeting transcription factors via regulome profiling
Platform: MARMOT native regulome profiling (functional proteomics + ML + chemistry)
Recent financing: Seed+ round led by Two Bear Capital (announced Aug 20, 2024)
Related Companies
| Company |
|---|
 |
 |
 |
 |
 |
Company Overview
Problem Domain
Drug discovery for diseases driven by genome regulators (oncology, rare disease, immune dysfunction, neurodegeneration).
Founded
2020
Industry
Biotechnology Research
Funding Track Record
9750000
Seed round closed; reported raise of $9.75M with participation from investors including NFX and Y Combinator.
11200000
Seed+ financing announced with participation from WRF Capital, NFX, YC Continuity Fund, FundersClub VC, and BoxOne Ventures.
Investor Signal
“Two Bear Capital led the Aug 20, 2024 Seed+ round; earlier investors include NFX and Y Combinator.”